Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLB | P06746 | 1/20 | 0.45 |
| ▸ | ABL1 | P00519 | 1/20 | 0.41 |
| ▸ | RIN1 | Q13671 | 1/20 | 0.41 |
| ▸ | DNMT1 | P26358 | 3/20 | 0.39 |
| ▸ | ADRB1 | P08588 | 1/20 | 0.39 |
| ▸ | TK1 | P04183 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21538134 | 0.91 | POLB (0.52) | POLBABL1RIN1DNMT1ADRB1 | |
| SCHEMBL25504696 | 0.90 | POLB (0.46) | POLBABL1RIN1DNMT1ADRB1 | |
| SCHEMBL21538138 | 0.86 | POLB (0.42) | POLBABL1RIN1 | |
| SCHEMBL30341923 | 0.84 | POLB (0.41) | POLBABL1RIN1 | |
| SCHEMBL25521895 | 0.83 | POLB (0.41) | POLBABL1RIN1DNMT1ADRB1 | |
| SCHEMBL9780708 | 0.83 | POLB (0.51) | POLBABL1RIN1DNMT1ADRB1 | |
| SCHEMBL9780701 | 0.83 | POLB (0.51) | POLBABL1RIN1DNMT1ADRB1 | |
| SCHEMBL9780702 | 0.82 | DNMT1 (0.45) | POLBDNMT1ADRB1 | |
| SCHEMBL9780709 | 0.82 | DNMT1 (0.45) | POLBDNMT1ADRB1 | |
| SCHEMBL5953531 | 0.82 | POLB (0.52) | POLBABL1RIN1DNMT1ADRB1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11787831-B2 | Nucleosides and nucleotides with 3′ acetal blocking group | ILLUMINA CAMBRIDGE LIMITED (GB) | 2023-10-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11787831-B2 | Nucleosides and nucleotides with 3′ acetal blocking group | DUT, ADAR, NT5C3B | POLB 113/4885ABL1 1809/4885RIN1 4075/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.